These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 30688661)
21. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development. Quemener AM; Centomo ML; Sax SL; Panella R Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851 [TBL] [Abstract][Full Text] [Related]
22. Antisense oligonucleotides: from design to therapeutic application. Chan JH; Lim S; Wong WS Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890 [TBL] [Abstract][Full Text] [Related]
23. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437 [TBL] [Abstract][Full Text] [Related]
24. Translating Antisense Technology into a Treatment for Huntington's Disease. Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033 [TBL] [Abstract][Full Text] [Related]
25. Does antisense make sense in dermatology? van Erp PE; Wingens M Acta Derm Venereol; 2001; 81(6):385-91. PubMed ID: 11859937 [TBL] [Abstract][Full Text] [Related]
26. Cellular uptake and trafficking of antisense oligonucleotides. Crooke ST; Wang S; Vickers TA; Shen W; Liang XH Nat Biotechnol; 2017 Mar; 35(3):230-237. PubMed ID: 28244996 [TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotides in therapy for neurodegenerative disorders. Evers MM; Toonen LJ; van Roon-Mom WM Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014 [TBL] [Abstract][Full Text] [Related]
28. The future of antisense oligonucleotides in the treatment of respiratory diseases. Ulanova M; Schreiber AD; Befus AD BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347 [TBL] [Abstract][Full Text] [Related]
29. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences. Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281 [TBL] [Abstract][Full Text] [Related]
34. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253 [TBL] [Abstract][Full Text] [Related]
35. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. McClorey G; Wood MJ Curr Opin Pharmacol; 2015 Oct; 24():52-8. PubMed ID: 26277332 [TBL] [Abstract][Full Text] [Related]
36. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051 [TBL] [Abstract][Full Text] [Related]
38. Preclinical and clinical pharmacology of antisense oligonucleotides. Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769 [TBL] [Abstract][Full Text] [Related]
39. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides. Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004 [TBL] [Abstract][Full Text] [Related]
40. An overview of sugar-modified oligonucleotides for antisense therapeutics. Prakash TP Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]